HiberCell Email Format

Biotechnology ResearchNew York, United States51-200 Employees

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

✕

Access Insights for HiberCell and Millions of Other Companies

Sign up for full access to HiberCell information. No credit card needed.

Continue with GoogleContinue with Microsoft

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory